Pepsa

# Pepsa ## Overview - **Classification**: Proton Pump Inhibitor (PPI) - **Mechanism**: Irreversibly blocks the H+/K+-ATPase pump in gastric parietal cells, leading to potent and prolonged inhibition of gastric acid secretion. ## Primary Indications 1. **Gastroesophageal Reflux Disease (GERD)** - Symptomatic relief and healing of erosive esophagitis. 2. **Peptic Ulcer Disease (PUD)** - Healing of duodenal and gastric ulcers. 3. **Zollinger-Ellison Syndrome (ZES)** - Management of pathological hypersecretory conditions. ## Adult Dosing ### Standard Dosing **Gastroesophageal Reflux Disease (GERD)** - **Dose**: **20 mg** - **Frequency**: Once daily - **Route**: Oral - **Duration**: 4-8 weeks for healing; up to 6 months for maintenance. **Peptic Ulcer Disease (PUD)** - **Duodenal Ulcer**: **20 mg** once daily for 4 weeks. - **Gastric Ulcer**: **40 mg** once daily for 8 weeks. - **Route**: Oral **Zollinger-Ellison Syndrome (ZES)** - **Dose**: Initial **60 mg** once daily. - **Frequency**: Adjust as needed, usually **20-120 mg/day**. - **Route**: Oral - **Special consideration**: Doses > **80 mg** may be given in divided doses. ### Dose Adjustments - **Renal Impairment**: No dose adjustment typically required. - **Hepatic Impairment**: For severe impairment (Child-Pugh C), consider maximum **20 mg** daily. - **Elderly Patients**: No specific dose adjustment needed; start with lowest effective dose. ## Pediatric Dosing ### Neonates (0-28 days) - **Dose**: Not recommended; safety and efficacy not established. - **Special Notes**: PPIs in neonates are generally off-label and require specialist consultation. ### Infants (1-12 months) **GERD (Erosive Esophagitis)** - **Dose**: **0.5 mg/kg** once daily. - **Frequency**: Once daily - **Maximum**: **10 mg** per day. - **Special Notes**: Use oral suspension or granules. Monitor for side effects closely. ### Children (1-12 years) **GERD (Erosive Esophagitis)** - **Weight < 20 kg**: **10 mg** once daily. - **Weight ≥ 20 kg**: **20 mg** once daily. - **Frequency**: Once daily - **Maximum**: **40 mg** (adult dose equivalent for most indications). - **Special Notes**: Use oral disintegrating tablets or suspension for easier administration. ### Adolescents (13-18 years) - **Dose**: Follow adult dosing guidelines. - **Maximum**: **40 mg** once daily for GERD/PUD; up to **120 mg** daily for ZES. ## Safety Information ### Contraindications - **Absolute**: Hypersensitivity to Pepsa or other PPIs. - **Absolute**: Concomitant use with rilpivirine-containing products. - **Relative**: History of severe hepatic impairment (use with caution). ### Common Adverse Effects - **Very Common (>10%)**: Headache, nausea, diarrhea. - **Common (1-10%)**: Abdominal pain, flatulence, constipation, dizziness. - **Serious but Rare**: *Clostridium difficile*-associated diarrhea, acute interstitial nephritis, bone fractures (long-term use), rhabdomyolysis. ### Key Drug Interactions - **Clopidogrel**: May reduce antiplatelet effect; consider alternative antiplatelet or PPI. - **Warfarin**: Increased INR/bleeding risk; monitor INR closely. - **Atazanavir/Nelfinavir**: Reduced absorption; avoid concomitant use. - **Methotrexate**: Increased methotrexate levels/toxicity; consider temporary PPI discontinuation. ## Monitoring & Follow-up - **Before Treatment**: Baseline assessment of symptoms and kidney function (CrCl). - **During Treatment**: Symptom resolution, monitoring for adverse effects. - **Long-term Use**: Consider monitoring Vitamin B12, magnesium levels, and bone mineral density. - **Clinical Signs**: Watch for persistent symptoms, signs of GI bleeding, or new severe diarrhea. ## Clinical Pearls - 💡 **Tip 1**: Administer **30-60 minutes before the first meal** of the day for optimal effect. - 💡 **Tip 2**: For ZES or severe reflux, **doses > 80 mg/day** should be divided. - 💡 **Tip 3**: Long-term use (>1 year) may increase risk of osteopenia/fractures; advise adequate calcium/Vitamin D intake. > **⚠️ Important**: This information is for educational purposes only. Always consult current prescribing information, local guidelines, and clinical judgment before prescribing.